Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.34 |
| ▸ | GPR183 | P32249 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2551138 | 1.00 | KDM4E (0.37) | KDM4EHRH3SLC6A2SLC6A4MEN1 | |
| SCHEMBL13419180 | 1.00 | KDM4E (0.37) | KDM4EHRH3SLC6A2SLC6A4MEN1 | |
| SCHEMBL30611837 | 0.98 | KDM4E (0.36) | KDM4EHRH3SLC6A2SLC6A4MEN1 | |
| Ammonia Solution, Strong SCHEMBL10987919 | 0.98 | KDM4E (0.36) | KDM4EHRH3SLC6A2SLC6A4MEN1 | |
| Hydrochloric Acid SCHEMBL4383352 | 0.98 | KDM4E (0.36) | KDM4EHRH3SLC6A2SLC6A4MEN1 | |
| SCHEMBL13772264 | 0.91 | SLC6A2 (0.37) | KDM4EHRH3SLC6A2SLC6A4MEN1 | |
| SCHEMBL14700537 | 0.86 | — | — | |
| Iodide SCHEMBL27681363 | 0.84 | KDM4E (0.31) | KDM4EHRH3 | |
| Fumaric Acid SCHEMBL7487053 | 0.83 | GPR183 (0.42) | KDM4ESLC6A2SLC6A4MEN1KMT2A | |
| Fumaric Acid SCHEMBL7487059 | 0.83 | GPR183 (0.42) | KDM4ESLC6A2SLC6A4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064215-B2 | Indazole benzimidazole compounds | CHIRON CORPORATION (US) | 2006-06-20 | — | — | US | claimed |
| EP-1401831-A1 | INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2004-03-31 | — | — | EP | claimed |
| US-20030207883-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2003-11-06 | — | — | US | claimed |
| WO-2003004488-A1 | INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-01-16 | — | — | WO | claimed |
| US-7642278-B2 | Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20070185013-A1 | Use of chk1 inhibitors to control cell proliferation | ICOS CORPORATION (US) | 2007-08-09 | — | — | US | disclosed |
| US-7064215-B2 | Indazole benzimidazole compounds | CHIRON CORPORATION (US) | 2006-06-20 | — | — | US | disclosed |
| EP-1667684-A1 | USE OF CHK1 INHIBITORS TO CONTROL CELL PROLIFERATION | ICOS Corporation (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20060079564-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2006-04-13 | — | — | US | disclosed |
| WO-2005027907-A1 | USE OF CHK1 INHIBITORS TO CONTROL CELL PROLIFERATION | ICOS CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
| EP-1401831-A1 | INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030207883-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2003-11-06 | — | — | US | disclosed |
| WO-2003004488-A1 | INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
| EP-0273307-B1 | METHOD OF TRANSFERRING CATIONIC DYES IN THEIR DE-PROTONATED, ELECTRICALLY NEUTRAL FORM | BASF Aktiengesellschaft (DE) | 1992-06-10 | — | — | EP | disclosed |
| EP-0275381-B1 | DYE TRANSFER PROCESS | BASF Aktiengesellschaft (DE) | 1992-03-04 | — | — | EP | disclosed |
| US-4880769-A | CYANINE, PHENOXAZINE DYES | BASF AKTIENGESELLSCHAFT (DE) | 1989-11-14 | — | — | US | disclosed |
| EP-0275381-A2 | Dye transfer process | BASF Aktiengesellschaft (DE) | 1988-07-27 | — | — | EP | disclosed |
| US-4760049-A | Dye transfer | BASF AKTIENGESELLSCHAFT (DE) | 1988-07-26 | — | — | US | disclosed |
| EP-0273307-A2 | Method of transferring cationic dyes in their de-protonated, electrically neutral form | BASF Aktiengesellschaft (DE) | 1988-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079564-A1 | Indazole benzimidazole compounds | ABL1, ABL2, ALK | KDM4E 2648/4885HRH3 2280/4885SLC6A2 2738/4885 |
| US-20070185013-A1 | Use of chk1 inhibitors to control cell proliferation | CHEK1, CHEK2, CDC25C | KDM4E 1263/4885HRH3 3197/4885SLC6A2 4764/4885 |
| US-20030207883-A1 | Indazole benzimidazole compounds | SLCO1B3, SLCO1B1, SLCO4C1 | KDM4E 3618/4885HRH3 1052/4885SLC6A2 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.